PACAP (6-38) (human, chicken, mouse, ovine, porcine, rat) (trifluoroacetate salt) (Synonyms: Pituitary Adenylate Cyclase-activating Peptide (6-38)) |
Katalog-Nr.GC44534 |
Pituitary adenylate cyclase-activating peptide (PACAP) (6-38) is a PACAP receptor antagonist with IC50 values of 30, 600, and 40 nM, respectively for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
Pituitary adenylate cyclase-activating peptide (PACAP) (6-38) is a PACAP receptor antagonist with IC50 values of 30, 600, and 40 nM, respectively for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors in rat brain membrane (IC50 = 39.14 nM) and to SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 2.9, 129, and 227 nM, respectively). In vivo, in newborn pigs, PACAP (6-38) (10 μM) inhibits vasodilation of pial arterioles induced by PACAP (1-38) , the full-length peptide. It also inhibits decreased food intake and reduced body weight in rats induced by cocaine- and amphetamine-regulated transcript peptides (CARTp) following intracerebroventricular administration of 0.3-3 mol per animal doses.
Average Rating: 5
(Based on Reviews and 12 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *